Keyphrases
Phase I Trial
100%
Bortezomib
100%
Carboplatin
100%
Primary Peritoneal Cancer
100%
Neurotoxicity
37%
Pharmacodynamics
37%
Area under the Curve
25%
Nuclear factor-κB
25%
Dose Reduction
25%
Complete Response
25%
Functional Assessment of Cancer Therapy
25%
Gynecologic Oncology Group
25%
Neurologist
12%
Neuropathy
12%
Dose Level
12%
Maximum Tolerated Dose
12%
Overall Response Rate
12%
Constipation
12%
Recurrent Disease
12%
Increased Dose
12%
Diarrhea
12%
Computed Tomography
12%
Chemotherapy Regimen
12%
2-cycles
12%
Upfront Chemotherapy
12%
Rash
12%
2-dose
12%
Partial Response
12%
Neurological Examination
12%
Fixed-dose Combination
12%
Prior Chemotherapy
12%
Dose-limiting Toxicity
12%
Recommended Phase 2 Dose
12%
Inhibition Rate
12%
Recurrent Ovarian Cancer
12%
Appropriate Dose
12%
20S Proteasome
12%
Platinum-resistant Disease
12%
Colonic Wall Thickening
12%
Medicine and Dentistry
Carboplatin
100%
Bortezomib
100%
Primary Peritoneal Cancer
100%
Phase I Trials
100%
Pharmacodynamics
37%
Neurotoxicity
37%
Functional Assessment
25%
Immunoglobulin Enhancer Binding Protein
25%
Cancer Therapy
25%
Drug Dose Reduction
25%
Gynecological Oncology
25%
Recurrent Disease
12%
Chemotherapy
12%
Computer Assisted Tomography
12%
Patient History of Chemotherapy
12%
Diarrhea
12%
Exanthem
12%
Neuropathy
12%
Constipation
12%
Recurrent Ovarian Cancer
12%
Proteasome
12%
Diseases
12%
Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
Bortezomib
100%
Peritoneum Cancer
100%
Carboplatin
100%
Neurotoxicity
37%
Pharmacodynamics
37%
Chemotherapy
25%
Malignant Neoplasm
25%
Immunoglobulin Enhancer Binding Protein
25%
Recurrent Disease
12%
Patient History of Chemotherapy
12%
Ovary Cancer
12%
Rash
12%
Diarrhea
12%
Neuropathy
12%
Constipation
12%
Maximum Tolerated Dose
12%
Proteasome
12%
Diseases
12%